TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

For the full year, Gilead now expects earnings per-share between 5 cents to 25 cents, compared with its prior view of zero cents to 30 cents. On an adjusted basis, the company expects earnings per ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...

Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...